Download PDF
Aktuelle Dermatologie 2002; 28(8/9): 314-318
DOI: 10.1055/s-2002-33967
Tumormarker
© Georg Thieme Verlag Stuttgart · New York

Prognoseevaluation mittels Immunhistologie

Immunohistology for Prognostic EvaluationJ.  Kamarashev1 , G.  Burg1 , W.  Kempf1 , R.  Dummer1
  • 1Dermatologische Klinik, Universitäts-Spital Zürich
Further Information

Publication History

Publication Date:
10 September 2002 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die Tumordicke ist der wichtigste prognostische Parameter für kutane Melanome. Jedoch wäre es wünschenswert mit zusätzlichen Untersuchungen die Prognose des individuellen Patienten weiter abzusichern. Bewährt haben sich in diesem Zusammenhang in mehreren Studien Proliferationsmarker und auch Adhäsionsmoleküle sowie immunologisch relevante Moleküle wie TAP1, das in der Antigenverarbeitung benötigt wird.

Abstract

The tumor thickness is the most important prognostic parameter for cutaneous melanoma. However, additional examinations are desirable to predict the prognosis of the individual patient. In this context, proliferation markers and also adhesion molecules as well as immunological relevant molecules such as TAP1, which is involved in antigen processing, have been shown to be of prognostic relevance.

Literatur

  • 1 Berwick M, Halpern A. Melanoma epidemiology.  Curr Opin Oncol. 1997;  9 178-182
    PubMedGoogle Scholar
  • 2 Häffner A C, Garbe C, Burg G, Buttner P, Orfanos C E, Rassner G. The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.  Br J Cancer. 1992;  66 856-861
    PubMedGoogle Scholar
  • 3 Dummer R, Bösch U, Panizzon R, Bloch P H, Burg G. für die Fachkommission „Hautkrebs” . Swiss Guidelines for the treatment and follow-up of cutaneous melanoma.  Dermatology. 2001;  203 75-80
    CrossrefPubMedGoogle Scholar
  • 4 Thorn M, Ponten F, Bergstrom R, Sparen P, Adami H O. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.  J Natl Cancer Inst. 1994;  86 761-769
    PubMedGoogle Scholar
  • 5 Karakousis C P, Driscoll D L. Prognostic parameters in localised melanoma: gender versus anatomical location.  Eur J Cancer. 1995;  3 320-324
    PubMedGoogle Scholar
  • 6 Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H. et al . Primary cutaneous melanoma. Prognostic classification of anatomic location.  Cancer. 1995;  75 2492-2498
    PubMedGoogle Scholar
  • 7 Ramsay J A, From L, Iscoe N A, Kahn H J. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.  J Invest Dermatol. 1995;  105 22-26
    CrossrefPubMedGoogle Scholar
  • 8 Straume O, Sviland L, Akslen L A. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.  Clin Cancer Res. 2000;  6 1845-1853
    PubMedGoogle Scholar
  • 9 Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun H J. et al . Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance.  Anticancer Res. 2000;  20 1781-1785
    PubMedGoogle Scholar
  • 10 Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A. et al . Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study.  J Surg Oncol. 1999;  70 150-160
    CrossrefPubMedGoogle Scholar
  • 11 Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V. et al . Prognostic immunohistochemical markers of primary human melanomas.  Br J Dermatol. 2001;  145 203-209
    CrossrefPubMedGoogle Scholar
  • 12 Boni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.  J Am Acad Dermatol. 1996;  35 416-418
    CrossrefPubMedGoogle Scholar
  • 13 Sparrow L E, English D R, Taran J M, Heenan P J. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.  Am J Dermatopathol. 1998;  20 12-16
    CrossrefPubMedGoogle Scholar
  • 14 Hernberg M, Turunen J P, von Boguslawsky K, Muhonen T, Pyrhonen S. Prognostic value of biomarkers in malignant melanoma.  Melanoma Res. 1998;  8 283-291
    PubMedGoogle Scholar
  • 15 Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Franssila K. et al . MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.  Oncology. 1999;  57 242-252
    PubMedGoogle Scholar
  • 16 Gelsleichter L, Gown A M, Zarbo R J, Wang E, Coltrera M D. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.  Mod Pathol. 1995;  8 530-535
    PubMedGoogle Scholar
  • 17 Loggini B, Rinaldi I, Pingitore R, Cristofani R, Castagna M, Barachini P. Immunohistochemical study of 48 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance.  Tumori. 2001;  87 179-186
    PubMedGoogle Scholar
  • 18 Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator.  Arch Dermatol Res. 1995;  287 146-151
    CrossrefPubMedGoogle Scholar
  • 19 McGregor J M, Yu C C, Dublin E A, Barnes D M, Levison D A, MacDonald D M. p53 immunoreactivity in human malignant melanoma and dysplastic naevi.  Br J Dermatol. 1993;  128 606-611
    PubMedGoogle Scholar
  • 20 Lee C S, Pirdas A, Lee M W. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis.  Australas J Dermatol. 1995;  36 192-195
    PubMedGoogle Scholar
  • 21 Karjalainen J M, Eskelinen M J, Kellokoski J K, Reinikainen M, Alhava E M, Kosma V M. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.  Br J Cancer. 1999;  79 895-902
    CrossrefPubMedGoogle Scholar
  • 22 Weiss J, Heine M, Korner B, Pilch H, Jung E G. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.  Br J Dermatol. 1995;  133 23-31
    PubMedGoogle Scholar
  • 23 Straume O, Akslen L A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma.  Int J Cancer. 1997;  74 535-539
    CrossrefPubMedGoogle Scholar
  • 24 Fernando S S, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody.  Pathology. 1994;  26 16-19
    PubMedGoogle Scholar
  • 25 Mirecka J, Korabiowska M, Schauer A. Comparative distribution of S-100 protein and antigen HMB-45 in various types of melanomas and naevi.  Pol J Pathol. 1995;  46 167-172
    PubMedGoogle Scholar
  • 26 Hofbauer G F, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle F O. et al . MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.  Am J Pathol. 1997;  151 1549-1553
    PubMedGoogle Scholar
  • 27 Hofbauer G F, Kamarashev J, Geertsen R, Boni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.  Melanoma Res. 1998;  8 337-343
    CrossrefPubMedGoogle Scholar
  • 28 Hofbauer G F, Kamarashev J, Geertsen R, Boni R, Dummer R. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.  J Cutan Pathol. 1998;  25 204-209
    PubMedGoogle Scholar
  • 29 Kageshita T, Kawakami Y, Ono T. Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients.  J Dermatol Sci. 2001;  25 36-44
    CrossrefPubMedGoogle Scholar
  • 30 Busam K J, Iversen K, Berwick M, Spagnoli G C, Old L J, Jungbluth A A. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.  Med Pathol. 2000;  13 459-465
    PubMedGoogle Scholar
  • 31 Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle F O, Burg G. et al . TAPI down-regulation in primary melanoma lesions: an independent marker of poor prognosis.  Int J Cancer. 2001;  95 23-28
    CrossrefPubMedGoogle Scholar
  • 32 Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V. et al . Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?.  Cancer. 1999;  85 2391-2399
    CrossrefPubMedGoogle Scholar
  • 33 Townsend S E, Allison J P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.  Science. 1993;  259 368-370
    PubMedGoogle Scholar
  • 34 Natali P G, Hamby C V, Felding-Habermann B, Liang B, Nicotra M R, DiFilippo F. et al . Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.  Cancer Res. 1997;  57 1554-1560
    PubMedGoogle Scholar
  • 35 Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki B M. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels.  J Natl Cancer Inst. 1995;  87 366-371
    CrossrefPubMedGoogle Scholar
  • 36 Natali P, Nicotra M R, Cavaliere R, Bigotti A, Romano G, Temponi M. et al . Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions.  Cancer Res. 1990;  50 1271-1278
    PubMedGoogle Scholar
  • 37 Becker J C, Dummer R, Burg G, Schmidt R E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and TNF-alpha: Functional consequences on cell mediated cytotoxicity.  J Immunol. 1991;  147 4398-4401
    PubMedGoogle Scholar
  • 38 Ciotti P, Pesce G P, Cafiero F, Rainero M L, Sementa A, Nicolo G. et al . Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions.  Melanoma Res. 1999;  9 253-260
    PubMedGoogle Scholar
  • 39 Podhajcer O L, Bover L, Bravo A I, Ledda M F, Kairiyama C, Calb I. et al . Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi.  J Invest Dermatol. 1995;  104 340-344
    CrossrefPubMedGoogle Scholar
  • 40 Goldmann T, Ribbert D, Suter L, Brode M, Otto F. Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics.  J Exp Clin Cancer Res. 1998;  17 483-489
    PubMedGoogle Scholar
  • 41 Vaisanen A, Kallioinen M, Taskinen P J, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72kD type IV collagenase) in primary skin melanoma.  J Pathol. 1998;  186 51-58
    PubMedGoogle Scholar
  • 42 Massi D, Franchi A, Borgognoni L, Reali U M, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.  Hum Pathol. 1999;  30 339-344
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Reinhard Dummer

Dermatologische Klinik · Universitäts-Spital Zürich

Gloriastraße 31 · 8091 Zürich · Schweiz

Email: reinhard.dummer@der.usz.ch

      >